- The company intimated two scheduled events: a Flagship institutional investor conference, INDX 2026 on Wednesday, November 18, 2026, at 10:00 A.M. IST at the Grand Hyatt, Mumbai, and an Institutional Investor Meet on Friday, November 20, 2026, at 10:00 A.M. IST at the Doddaballapur plant. Both events are organized by Avendus Spark.
- The mode of meeting will be individual/institutional investors in 1:1 physical and/or group meetings.
- The stated purpose is for discussions based on publicly available information. The company explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these interactions.
- An Investor Presentation for the analyst meet was enclosed with the disclosure and is also available on the company's website at www.indo-mim.com.
Financial Highlights from Enclosed Presentation (H1 FY27 ended 30 September 2026)
The enclosed earnings review presentation provided detailed financial results for H1 FY27.
Consolidated P&L Snapshot (₹ Crore):
- Revenue from operations: ₹2,490.58 (vs. H1 FY26: ₹2,226.75), a growth of +11.8% YoY.
- EBITDA: ₹803.41 (vs. H1 FY26: ₹582.42), a growth of +37.9% YoY.
- EBITDA margin: 32.0% (vs. H1 FY26: 25.7%), an expansion of ~630 bps.
- Profit before Exceptional Items and tax: ₹634.78 (vs. H1 FY26: ₹487.41), a growth of +30.2% YoY.
- Profit after tax (PAT): ₹455.31 (vs. H1 FY26: ₹290.03), a growth of +57.0% YoY.
- Net margin: 18.2% (vs. H1 FY26: 12.8%), an expansion of ~540 bps.
- Basic EPS: ₹9.34 (vs. H1 FY26: ₹6.02), a growth of +55.2% YoY.
- Diluted EPS: ₹9.18 (vs. H1 FY26: ₹5.88), a growth of +55.9% YoY.
Standalone P&L Snapshot (₹ Crore):
- Revenue from operations: ₹2,073.1 (vs. H1 FY26: ₹1,927.70), a growth of +7.5% YoY.
- EBITDA: ₹741.6 (vs. H1 FY26: ₹641.1), a growth of +15.7% YoY.
- EBITDA margin: 35.5% (vs. H1 FY26: 32.7%), an expansion of ~280 bps.
- PAT: ₹443.5 (vs. H1 FY26: ₹292.38), a growth of +51.7% YoY.
- Net margin: 21.2% (vs. H1 FY26: 14.9%), an expansion of ~630 bps.
Key Performance Drivers:
- The strong profitability and margin expansion were attributed to higher contribution from defence and medical segments, including tooling income.
- Management provided a sustainable EBITDA margin framework of 20–25% as a base, with upside in years where defence or medical revenue carries a higher mix.
- H1 FY27 Return on Capital Employed (ROCE) was 36.5% (up 570 bps) and Return on Equity (ROE) was 26.3%.
- Debt-to-equity improved to 0.27x from 0.50x in the previous period.
- The cash conversion cycle increased to 417 days (H1 FY26: 324 days), with debtor days at 64, inventory days at 441, and payable days at 88.
Revenue Breakdown - Consolidated (₹ Crore):
By Product Group:
- MIM: ₹1,500.1 (60% of mix), +19.8% YoY
- IC: ₹477.2 (19% of mix), +36.0% YoY
- Machining: ₹188.2 (8% of mix), +55.4% YoY
- Medical Devices: ₹23.2 (1% of mix), -7.1% YoY
- Powders: ₹20.8 (1% of mix), +25.1% YoY
- Others: ₹281.0 (11% of mix), -39.0% YoY
By End-Market Segment:
- AEPG (Aerospace): ₹223.9 (9% of mix), +31.5% YoY
- APG (Automotive): ₹615.6 (25% of mix), +19.4% YoY
- CPG (Consumer): ₹389.5 (16% of mix), +46.2% YoY
- DPG (Defence): ₹493.8 (20% of mix), +19.3% YoY
- MPG (Medical): ₹475.3 (19% of mix), +22.7% YoY
- Powder, tools, traded: ₹24.4 (1% of mix), +11.2% YoY
- ECM (electronics): ₹268.1 (11% of mix), -40.5% YoY
Subsidiaries: The document lists subsidiaries including Indo-MIM Inc. USA, Triax Industries, Conway Marsh Garrett Technologies, Phoenix DeVentures, and Indo-MIM Arms Components. Standalone revenue constitutes ~83% of consolidated revenue.
Outlook and Guidance:
- Management provided full-year FY27 targets for revenue and bottom line.
- It was stated that management expects to do better than these targets and will provide a further update after Q3 FY27.
Additional Notes Section
- The disclosure included an enclosed Investor Presentation titled "H1 FY2026-27 EARNINGS REVIEW".
- Significant financial data was disclosed in the enclosed presentation, including full H1 FY27 results, segmental breakdowns, and key metrics.